Skip to search formSkip to main contentSkip to account menu

Iniparib

Known as: 4-iodo-3-nitrobenzamide, SAR240550 
A small molecule iodobenzamide with potential cytotoxic and antineoplastic activities. Although the mechanism of action is unknown, iniparib appears… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (1)

BSI 201

Broader (2)

BenzamidesPoly(ADP-ribose) Polymerase Inhibitors
NCIt Antineoplastic Agent TerminologyPARP1 protein, human

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines
Purpose Trabectedin induces synthetic lethality in tumor cells carrying defects in homologous recombinant DNA repair. We… 
2013
2013
PARP inhibitors bounce back
A series of setbacks almost caused the demise of PARP inhibitors, but four companies are now beginning pivotal trials of these… 
Review
2013
Review
2013
Newer Therapies for the Treatment of Metastatic Breast Cancer: a Clinical Update
Breast cancer is the foremost common malignancy among the female population around the world. Female breast cancer incidence… 
Review
2012
Review
2012
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.
As recruitment for oncology clinical trials has become more difficult, there appears to have been an increase in the number of… 
Review
2011
Review
2011
PARP inhibitors--current status and the walk towards early breast cancer.
2011
2011
A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer.
5005 Background: Recurrent ovarian cancer following treatment of advanced disease with platinum-based therapy, such as GC, is… 
2011
2011
All PARP inhibitors are not equal: An in vitro mechanistic comparison of PF-01367338 to iniparib.
e13576 Background: PARP is a key enzyme involved in base-excision repair. Pre-clinically it has been shown that BRCA1/2 deficient… 
Review
2010
Review
2010
Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer.
PARP inhibitors are a promising, novel class of anticancer agents. Iniparib (BSI-201) is an intravenously administered PARP1… 
2009
2009
Enzymatic mechanism of the tumoricidal action of 4-iodo-3-nitrobenzamide.
Activation of the prodrug 4-iodo-3-nitrobenzamide critically depends on the cellular reducing system specific to cancer cells. In… 
2002
2002
Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)